Literature DB >> 9027644

Analysis of serum hepatitis A virus antibody response in different courses of hepatitis A virus infection.

M Sata1, H Nakano, E Tanaka, R Kumashiro, H Suzuki, K Tanikawa.   

Abstract

Changes in the serum hepatitis A virus antibody (anti-HAV) response in patients with different clinical courses of HAV infection were examined using immune adherence hemagglutination (IAHA). Anti-HAV was detected 2-6 weeks after the onset of clinical symptoms in patients with the typical course of acute hepatitis A and 1-4 weeks after the onset in those with fulminant hepatitis A. Maximal anti-HAV titers were observed 8-20 weeks after the onset of clinical symptoms, and changes in anti-HAV were similar in the typical and the prolonged course of acute hepatitis A, but maximal antibody titers were higher in the prolonged course. Maximal anti-HAV titers in patients with subclinical HAV infection were significantly lower than titers in patients with the typical and prolonged courses of acute hepatitis A, and in those with fulminant hepatitis A. High titers of anti-HAV remained positive for at least 6 years after infection in patients with clinical infection and for at least 4 years in patients with subclinical infection on follow-up. These findings suggest that the maximum anti-HAV titer correlates with the clinical severity of HAV infection; knowledge of the antibody response should be useful for analyzing the pathogenesis of HAV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9027644     DOI: 10.1007/bf02358607

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  22 in total

1.  The antibody response following hepatitis A infection.

Authors:  S A Locarnini; A A Ferris; N I Lehmann; I D Gust
Journal:  Intervirology       Date:  1977       Impact factor: 1.763

2.  Fulminant hepatitis A.

Authors:  L R Mathiesen; T Linglöf; A M Møller; B Tufvesson; T Johnsson; F Nordbring
Journal:  Scand J Infect Dis       Date:  1979

3.  Hepatitis A virus in stool during clinical relapse.

Authors:  M H Sjogren; H Tanno; O Fay; S Sileoni; B D Cohen; D S Burke; R J Feighny
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

4.  Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers.

Authors:  R D Woodson; J J Clinton
Journal:  JAMA       Date:  1969-08-18       Impact factor: 56.272

5.  Fulminant type A viral hepatitis in a chimpanzee.

Authors:  K Abe; T Shikata
Journal:  Acta Pathol Jpn       Date:  1982-01

6.  Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.

Authors:  K Midthun; E Ellerbeck; K Gershman; G Calandra; D Krah; M McCaughtry; D Nalin; P Provost
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

7.  Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay.

Authors:  D W Bradley; J E Maynard; S H Hindman; C L Hornbeck; H A Fields; K A McCaustland; E H Cook
Journal:  J Clin Microbiol       Date:  1977-05       Impact factor: 5.948

8.  Effect of immunoglobulin on hepatitis A in day-care centers.

Authors:  S C Hadler; J J Erben; D Matthews; K Starko; D P Francis; J E Maynard
Journal:  JAMA       Date:  1983-01-07       Impact factor: 56.272

9.  Serum IgA anti-hepatitis A virus as detected by enzyme-linked immunosorbent assay. Diagnostic significance in patients with acute and protracted hepatitis A.

Authors:  G Angarano; F Trotta; L Monno; T Santantonio; G Pastore
Journal:  Diagn Microbiol Infect Dis       Date:  1985-11       Impact factor: 2.803

10.  Time course of hepatitis A virus antibody titer after active and passive immunization.

Authors:  S Fujiyama; S Iino; K Odoh; S Kuzuhara; H Watanabe; M Tanaka; K Mizuno; T Sato
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.